Everyone should read this Article and give feedback to it:

New Post Public Reply Private Reply Replies (1) Message Board
BrownMule mikeyt1818 #10130
1,477
Everyone should read this Article and give feedback to it: We see all the TV Ads about all these FDA approved Meds and then the list goes on an on about the side affects from taking the Med. then the FDA puts a Article out stating all this BS about CBD I have taken it for (4) years now with wonderful side effects, my sugar is under control(eat what I want), my blood pressure stays normal, hardly ever have any pain, stay active everyday doing something. I could write a nice Article about all the GOOD from the hemp plant just from my experience with CBD, only problem is my typing don't always match my thoughts.....


You may have noticed that cannabidiol (CBD) seems to be available almost everywhere, and marketed as a variety of products including drugs, food, dietary supplements, cosmetics, pet food, and other animal health products.
The U.S. Food and Drug Administration (FDA) recognizes the significant public interest in cannabis and cannabis-derived compounds, particularly CBD. However, there are many unanswered questions about the science, safety, and quality of products containing CBD.

The Agency is working on answering these questions through ongoing efforts including feedback from a recent FDA hearing and information and data gathering through a public docket that is open for comment until July 16, 2019.

The recent increase in the number of CBD products may be because of both recent changes in state law, and because the 2018 Farm Bill removed hemp — defined as cannabis and cannabis derivatives with very low concentrations (no more than 0.3% on a dry weight basis) of THC — from the definition of marijuana in the Controlled Substances Act. However, CBD products are still subject to the same laws and requirements as FDA-regulated products that contain any other substance.
Other than one prescription drug product to treat rare, severe forms of epilepsy, the FDA has not approved any other CBD products, and there is very limited available information about CBD, including about its effects on the body.
The FDA is working to learn more about the safety of CBD and CBD products. More specifically:
The effects CBD could cause in the body, such as toxicity to the liver, when someone ingests CBD regularly over a long period of time. During its review of the marketing application for Epidiolex — a purified form of CBD that the FDA approved in 2018 for use in the treatment of certain seizure disorders — the FDA identified certain safety risks, including the potential for liver injury. These are serious risks that can be managed when an FDA-approved CBD drug product is taken under medical supervision, but it is less clear how these risks might be managed when CBD is used far more widely, without medical supervision and not in accordance with FDA-approved labeling.
The cumulative exposure to CBD if people access it across a broad range of consumer products. For example, what happens if you eat food with CBD in it, use CBD-infused skin cream and take other CBD-based products on the same day? What if you use these products daily for a week or a month?
The effects of CBD on special populations (e.g., the elderly, children, adolescents, pregnant and lactating women) or types of animals (e.g., species, breed, or class).
The safety of CBD use in animals (e.g., species, breed, or class) including pets.
Some CBD Products are Being Marketed with Unproven Medical Claims
Unlike drug products approved by the FDA, unapproved CBD drug products have not been subject to FDA review as part of the drug approval process, and there has been no FDA evaluation regarding whether they are safe and effective to treat a particular disease, what the proper dosage is, how they could interact with other drugs or foods, or whether they have dangerous side effects or other safety concerns.
Misleading and false claims associated with CBD products may lead consumers to put off getting important medical care, such as proper diagnosis, treatment, and supportive care. For that reason, it’s important to talk to your doctor about the best way to treat diseases or conditions with existing, approved treatment options.
The FDA’s top priority is to protect the public health, and that includes making sure consumers know about products that put their health and safety at greatest risk, such as those claiming to prevent, diagnose, treat, or cure serious diseases. For example, the agency has warned companies selling CBD products they claim are intended to prevent, diagnose, treat, or cure serious diseases such as cancer, Alzheimer’s disease, psychiatric disorders and diabetes.
The FDA has also tested the chemical content of cannabinoid compounds in some of the products, and many were found to not contain the levels of CBD they claimed to contain. We have also heard reports of CBD potentially containing contaminants (e.g., pesticides, heavy metals); we are looking into this.
Some cannabis products are also being marketed as pet food and health products for animals. The FDA has not approved cannabis for any use in animals and recommends pet owners talk with their veterinarians about appropriate treatment options for their pets.
The FDA is Continuing to Evaluate the Regulatory Frameworks for Products Containing Cannabis and Cannabis-Derived Compounds
The FDA continues to believe the drug approval process represents the best way to help ensure that safe and effective new medicines, including any drugs derived from cannabis, are available to patients in need of appropriate medical therapy. The Agency is committed to supporting the development of new drugs, including cannabis and cannabis-derived drugs, through the investigational new drug and drug approval process.
We are aware that there may be some products on the market that add CBD to a food or label CBD as a dietary supplement. Under federal law, it is currently illegal to market CBD this way.
The FDA is currently evaluating the regulatory frameworks that apply to certain cannabis-derived products that are intended for non-drug uses, including whether and/or how the FDA might consider updating its regulations, as well as whether potential legislation might be appropriate. The information we have underscores the need for further study and high quality, scientific information about the safety and potential uses of CBD.
The FDA is committed to sound, science-based policy. The FDA is raising these safety, marketing and labeling concerns with you now because we want you to know what we know. We hope that you will provide any data that you have to the public docket.
Today’s Consumer Update includes a practical summary of what we know to date. As we learn more, our goal is to update you with the information you need to make smart choices about CBD products. Also, as the regulatory pathways are clarified we will take care to notify all stakeholders as quickly as possible.
More information is available at: FDA Regulation of Cannabis and Cannabis-Derived Products: Questions and Answers.

https://www.fda.gov/consumers/consumer-update...r-cannabis

Univec Conglomerate Inc (UNVC) Stock Research Links

UNVC Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CORE CEO Charts New Growth Path in Organ Donation

Updated Category News Views 3

Embracing New Horizons in Organ Donation In a whirlwind of change and commitment, Deborah Maurer steps up as CORE's new CEO, aiming to bring a fresh perspective to the organization's storied history. With her extensive experience at the transplant frontline, she's no rookie. She's got ambitions to shake things up, focusing on collaboration and innovation within the...

Continue Reading
Vertiv's Bold $1.45B Buyout to Enhance AI Data Centers

Updated Category News Views 5

Vertiv Snatches Up UtilityInnovation Group for $1.45 Billion Throw a stone into the tech sector, and it's bound to hit something about AI or data centers these days. Well, Vertiv Holdings Co. (NYSE: VRT) has made a splash by announcing a meaty $1.45 billion transaction to acquire UtilityInnovation Group (UIG). This move isn't just a bid to dust off the company's resume;...

Continue Reading
Balázs Nagy's Bold Move: Transforming AI Workforce

Updated Category News Views 0

New Horizons in AI: Balázs Nagy Leads There's always that one name that shakes things up, and today it's Balázs Nagy. The guy's not just playing in the AI sandbox; he's leveling the whole thing up with Project NoéMI. He's the big cheese at TheNewPush LLC, beyond just a job title. Nagy’s diving headfirst into AI workforce development in a world screaming for change....

Continue Reading
Baystate Noble Plans Major ED Expansion for Future Needs

Updated Category News Views 0

A Trusted Name in Healthcare Steps Up When a healthcare player like Baystate Health decides to jump into the deep end with an expansion project, you know they're not just doodling on napkins. With a legacy stretching back to 1883, Baystate Health, anchored deeply in western New England, isn't just expanding for fun—it's a move to cement its position as a crucial...

Continue Reading
Tolnai Joins UPCEA Leaders Pioneering Credential Innovations

Updated Category News Views 1

The Future of Education Shaped Today There's a profound shift happening in higher education, and it's not the usual undergrad grind most folks think of. Cate Tolnai, stepping into her role at the University of Phoenix, is in the thick of it. She's set to join the UPCEA Council for Credential Innovation's leadership team, and that isn't some fluff title. Her appointment...

Continue Reading
RealityMine Appoints CPO Amidst Strong Growth Momentum

Updated Category News Views 0

Pushing the Boundaries of Behavioral Data When a company like RealityMine posts a whopping 75% year-over-year revenue bump, you know they're not here to mess around. Enter Soumya Bijjal, a seasoned pro stepping in as their inaugural Chief Product Officer. This isn't just about adding to the C-suite boys' club; it's about locking in on a goldmine of behavioral data that's...

Continue Reading
Acer's New Monitors: ePaper, Triple Displays & More

Updated Category News Views 7

Next-Gen Screens: Breakthrough or Bust? So, Acer’s stepping up its game, unveiling an armory of gadgets designed to cement their spot in the tech arena. On the menu today? ePaper displays and enhanced connectivity gizmos that could either tip the scales or sink like a stone. Keep your eyes peeled, though—these updates aren't just another throwaway press release....

Continue Reading
Marco's Pizza Fuels Education with $1M Donation Boost

Updated Category News Views 1

It's not just about slinging pies for Marco's Pizza these days. They're marking a mighty milestone with a $1 million donation to Junior Achievement USA, a major player in prepping young folks to grapple with real-world financials and entrepreneurship. This hefty check not only pushes The Marco's Pizza Foundation's giving tally past the $1.5 million mark, but it also...

Continue Reading
Charter CFO to Speak at Citi TMT Conference 2026

Updated Category News Views 10

Charting Charter's Future Moves at the Citi TMT Conference There's something electric about a company like Charter Communications showing up at a big-deal event like the Citi Global TMT Conference. It's not just another day in the office when Jessica Fischer, the Chief Financial Officer, steps up to the mic on September 10, 2026. Investors better have their ears perked...

Continue Reading
Power Solutions Litigations Prompt Investor Caution

Updated Category News Views 0

A Storm Brews Over Power Solutions International Look, if you're holding Power Solutions International (NASDAQ:PSIX) in your portfolio, it's time to perk up. The air's thick with talk that Kuehn Law, the firm with a head for shareholder litigation, is on their case. They're poking around, seeing if some executives got a little too creative with the truth. Word on the...

Continue Reading

Top 5 Most Recently Viewed Articles

Valens Semiconductor Set to Reveal Q2 2025 Results Soon

Updated Category News Views 135

Valens Semiconductor to Announce Q2 2025 Financial Results Valens Semiconductor (NYSE: VLN), a leader in high-performance connectivity solutions, has officially shared news regarding its upcoming financial performance for the second quarter of 2025. The company will release these results ahead of the market opening. Investors and stakeholders can anticipate this...

Continue Reading
Investigating Mullen Automotive: A Call to Investors for Justice

Updated Category News Views 162

Understanding the Mullen Automotive Case Mullen Automotive, Inc. has caught the attention of investors and legal experts alike as significant allegations surface regarding potential violations of securities laws. As the market fluctuates, investors who have faced losses exceeding $75,000 within specific timeframes have been prompted to seek justice and explore their legal...

Continue Reading
Essential Strategies for Managing Commercial Auto Insurance

Updated Category News Views 280

Understanding Commercial Auto Insurance Mistakes In the world of business, managing commercial auto insurance is crucial. Sissy LeClair from Blackadar Insurance Agency Inc. sheds light on the frequent mistakes companies make regarding their coverage. This insightful discussion highlights the significance of diligent policy management. Common Missteps Businesses Make One...

Continue Reading
GoldHaven and Peers Drive Resource Growth Amid Market Thrills

Updated Category News Views 221

Gold Prices Spike as Resource Development Advances Gold prices have recently surged, maintaining levels above $4,200 per ounce, reflecting a steady interest from investors seeking safe-haven assets. The current market conditions invite exploration and drilling programs aimed at expanding existing mineral resources across various regions. Companies are reporting...

Continue Reading
Proton Pump Inhibitors Market Growth Driven by AI and Reformulation

Updated Category News Views 100

Proton Pump Inhibitors Market Growth Insights The global market for Proton Pump Inhibitors (PPIs) is witnessing impressive growth, with projections indicating an increase of USD 819.5 million from 2025 to 2029. The annual growth rate is expected to reach approximately 4.7% during this period. Various factors contribute to this upward trajectory, notably the driving force...

Continue Reading